Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes.
about
Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potentialEfficient hepatic delivery of drugs: novel strategies and their significanceStealth Properties to Improve Therapeutic Efficacy of Drug NanocarriersAdministration of liposomal agents and blood clearance capacity of the mononuclear phagocyte system.The role of pH and ring-opening hydrolysis kinetics on liposomal release of topotecan.Pharmacokinetics and urinary excretion of amikacin in low-clearance unilamellar liposomes after a single or repeated intravenous administration in the rhesus monkeyTargeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.Intratumoral versus intravenous gene therapy using a transcriptionally targeted viral vector in an orthotopic hepatocellular carcinoma rat model.pH-sensitive multi-PEGylated block copolymer as a bioresponsive pDNA delivery vector.Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis.Effects of chitosan coating on physical properties and pharmacokinetic behavior of mitoxantrone liposomesOptimization of PEGylation conditions for BSA nanoparticles using response surface methodology.Tumor-targeted RNA-interference: functional non-viral nanovectors.Comparative pharmacokinetics, distributions in tissue, and interactions with blood proteins of conventional and sterically stabilized liposomes containing 2',3'-dideoxyinosineInsights into accelerated liposomal release of topotecan in plasma monitored by a non-invasive fluorescence spectroscopic method.Ionizable amphiphilic dendrimer-based nanomaterials with alkyl-chain-substituted amines for tunable siRNA delivery to the liver endothelium in vivoPhosphatidylinositol induces fluid phase formation and packing defects in phosphatidylcholine model membranesPolymer-based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosisNano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance.Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour modelsMapping surface charge density of lipid bilayers by quantitative surface conductivity microscopyPlasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice.Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats.The influence of different long-circulating materials on the pharmacokinetics of liposomal vincristine sulfate.Ethanol treatment a Non-extrusion method for asymmetric liposome size optimization.Targeted pharmaceutical nanocarriers for cancer therapy and imagingNanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy.Liposomal daunorubicin as treatment for Kaposi's sarcomaTriggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomesA Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression In VivoMultifunctional and stimuli-sensitive pharmaceutical nanocarriers.Development of a novel lipophilic, magnetic nanoparticle for in vivo drug delivery.Surface engineering of liposomes for stealth behavior.Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearanceFactors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles.Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis.Drug delivery strategies to control macrophages for tissue repair and regeneration.Lipid Nanoparticle Systems for Enabling Gene Therapies.Advances in Lipid Nanoparticles for siRNA Delivery.Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo
P2860
Q24657256-452518D5-A02A-4971-9EEA-091F86425FE3Q27007518-B5CA0E88-4C55-4A57-97C9-012F19DD20A6Q27496024-ED3ED22D-8883-4FCE-873D-D71D8C0937E2Q33694095-02F8C561-1C50-4755-9458-AA439E329E75Q33925422-FF012304-D552-4FCC-81D0-8B847DBBAA4FQ33976387-5961214B-926D-4E9D-8E35-CD314637C291Q34025149-C3568A7C-7EFA-413A-8293-FFC5227044B7Q34042354-6A4AA314-C2D2-415F-A140-38F1C241554DQ34050052-983B9658-0599-46C9-9EF9-B25E099A7CB2Q34153033-74FDDBDE-038B-4CAD-B11B-EBCCAE5307DEQ34177514-FAC69B5E-8AAD-4F56-8270-47B964CFD5E1Q34280232-D17AEFB5-779E-4C70-A4DB-7405D11A55E5Q34974957-92437DAF-8181-4B65-8EE5-EC7F607F3848Q35122037-66D5FF1E-4ED5-40BE-8E18-CDF3F764E61EQ35166689-94D2D094-5950-423C-B26F-5A8FEED837FEQ35374908-1DA0C7F8-94A8-4549-A2C5-58296A3BE517Q35645401-9C33800C-F466-430F-A6DD-9C394CA3D838Q35710262-E15697BB-A7AA-4B87-A3A8-50A40F114F04Q36057394-CB207066-4D0C-4A35-B19A-4600426D4420Q36081662-BD67F008-43F5-4B6B-B8DC-DD29D8116FBFQ36113327-69ABD52C-1997-4BDE-AEF5-7F81DF74C912Q36115992-BE3B5A61-5A6D-4838-AC3A-D9754E2B7A15Q36125194-BFCC4C11-1D0D-471A-AE47-E62BEE2AAF21Q36129610-D041780D-8655-4F9F-8135-FFEEEB8A613FQ36798580-39CE7A23-5D0A-4451-AF48-D8813AAC4A7AQ36871933-353D1B0B-E527-4F63-8616-6397FB716F8EQ36933043-D3F0ADF0-82C8-436C-A4B0-3AC7D616E742Q37004096-0F6C0DEB-5A20-4E4B-B347-8A65E4707C57Q37026510-F3FE8D40-DB47-4D9D-BD69-6037DD9BF30CQ37258262-5DE1432E-8236-41F7-A575-AA26B1D301C7Q37314628-55A93615-7338-4E39-A839-C037363959A8Q37327883-B4E7581C-4ED2-46A9-8E9F-4A9A2D6A2ABEQ37415968-0D61F6A7-4DB5-46AE-8226-D6B6F63D7FA7Q37471523-63C5AFE7-7113-4D10-837C-68C7E8113621Q37476252-985D8C4D-1984-426E-9ED2-98D2A8E8DCA8Q37845396-7B3D8364-DC9C-451E-BB23-D5C84BC1A2E6Q38837041-EAEA91A6-08D5-4347-930B-9776EF4C12C3Q39244558-6570D7AE-186B-47B6-BC8C-D6018D655AA3Q41786279-6CCC14E6-52F0-4BD8-9367-37FF0C09FF61Q42723786-46FFCA08-59FF-4944-A314-532686D7F45A
P2860
Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes.
description
1992 nî lūn-bûn
@nan
1992 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Association of blood proteins ...... tion to circulation lifetimes.
@ast
Association of blood proteins ...... tion to circulation lifetimes.
@en
Association of blood proteins ...... tion to circulation lifetimes.
@nl
type
label
Association of blood proteins ...... tion to circulation lifetimes.
@ast
Association of blood proteins ...... tion to circulation lifetimes.
@en
Association of blood proteins ...... tion to circulation lifetimes.
@nl
prefLabel
Association of blood proteins ...... tion to circulation lifetimes.
@ast
Association of blood proteins ...... tion to circulation lifetimes.
@en
Association of blood proteins ...... tion to circulation lifetimes.
@nl
P2093
P1476
Association of blood proteins ...... tion to circulation lifetimes.
@en
P2093
P304
18759-18765
P407
P577
1992-09-01T00:00:00Z